121 related articles for article (PubMed ID: 12823619)
1. Influence of 1-aminocyclohexane-1-carboxylic acid in position 2 or 3 of AVP and its analogues on their pharmacological properties.
Jastrzebska B; Derdowska I; Kowalczyk W; Machova A; Slaninová J; Lammek B
J Pept Res; 2003 Aug; 62(2):70-7. PubMed ID: 12823619
[TBL] [Abstract][Full Text] [Related]
2. Raman and surface-enhanced Raman spectroscopy investigation of vasopressin analogues containing 1-aminocyclohexane-1-carboxylic acid residue.
Podstawka E; Sikorska E; Proniewicz LM; Lammek B
Biopolymers; 2006 Oct; 83(2):193-203. PubMed ID: 16741975
[TBL] [Abstract][Full Text] [Related]
3. Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
Kowalczyk W; Prahl A; Derdowska I; Dawidowska O; Slaninová J; Lammek B
J Med Chem; 2004 Nov; 47(24):6020-4. PubMed ID: 15537356
[TBL] [Abstract][Full Text] [Related]
4. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
5. The influence of 1-aminocyclopentane-1-carboxylic acid at position 2 or 3 of AVP and its analogues on their pharmacological properties.
Kowalczyk W; Prahl A; Dawidowska O; Derdowska I; Sobolewski D; Hartrodt B; Neubert K; Slaninová J; Lammek B
J Pept Sci; 2005 Sep; 11(9):584-8. PubMed ID: 15747318
[TBL] [Abstract][Full Text] [Related]
6. Influence of conformationally constrained amino acids replacing positions 2 and 3 of arginine vasopressin (AVP) and its analogues on their pharmacological properties.
Sobolewski D; Prahl A; Derdowska I; Kwiatkowska A; Slaninová J; Lammek B
Protein Pept Lett; 2007; 14(3):213-7. PubMed ID: 17346223
[TBL] [Abstract][Full Text] [Related]
7. Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties.
Lammek B; Czaja M; Derdowska I; Rekowski P; Trzeciak HI; Sikora P; Szkróbka W; Stojko R; Kupryszewski G
J Pept Res; 1997 Mar; 49(3):261-8. PubMed ID: 9151259
[TBL] [Abstract][Full Text] [Related]
8. Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
Kwiatkowska A; Sobolewski D; Prahl A; Borovicková L; Slaninová J; Lammek B
Eur J Med Chem; 2009 Jul; 44(7):2862-67. PubMed ID: 19418631
[TBL] [Abstract][Full Text] [Related]
9. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
[TBL] [Abstract][Full Text] [Related]
10. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
11. Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanine.
Lammek B; Konieczna E; Trzeciak HI; Kozłowski A; Szymkowiak J; Stojko R; Kupryszewski G
J Pharm Pharmacol; 1996 Mar; 48(3):316-9. PubMed ID: 8737061
[TBL] [Abstract][Full Text] [Related]
12. Analogues of arginine vasopressin and its agonist and antagonist modified in the N-terminal part of the molecule with l-beta-homophenylalanine.
Sobolewski D; Kowalczyk W; Prahl A; Derdowska I; Slaninová J; Zabrocki J; Lammek B
J Pept Res; 2005 Apr; 65(4):465-71. PubMed ID: 15813895
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
[TBL] [Abstract][Full Text] [Related]
14. Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.
Howl J; Prochazka Z; Wheatley M; Slaninová J
Br J Pharmacol; 1999 Oct; 128(3):647-52. PubMed ID: 10516644
[TBL] [Abstract][Full Text] [Related]
15. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological activity of new neurohypophyseal hormones analogues conformationally restricted in the N-terminal part of the molecule. Highly potent OT receptor antagonists.
Kwiatkowska A; Ptach M; Borovičková L; Slaninová J; Lammek B; Prahl A
Amino Acids; 2012 Aug; 43(2):617-27. PubMed ID: 22038179
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
18. Biologically active analogues of arginine vasopressin containing conformationally restricted dipeptide fragments.
Lammek B; Czaja M; Derdowska I; Lempicka E; Sikora P; Szkróbka W; Trzeciak HI
J Pept Res; 1998 Feb; 51(2):149-54. PubMed ID: 9516050
[TBL] [Abstract][Full Text] [Related]
19. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: selective antagonists of oxytocin in-vitro.
Sobocińska M; Lempicka E; Konieczna E; Derdowska I; Lammek B; Melhem S; Kozik W; Janecka J; Janecki M; Trzeciak HI
J Pharm Pharmacol; 2000 Sep; 52(9):1105-12. PubMed ID: 11045891
[TBL] [Abstract][Full Text] [Related]
20. The effects of N-terminal part modification of arginine vasopressin analogues with 2-aminoindane-2-carboxylic acid: a highly potent V2 agonist.
Kowalczyk W; Sobolewski D; Prahl A; Derdowska I; Borovicková L; Slaninová J; Lammek B
J Med Chem; 2007 Jun; 50(12):2926-9. PubMed ID: 17500550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
